OS benefit of adjuvant osimertinib in resected EGFR-mutated NSCLC persists at 8th year

6 hours ago
Elvira Manzano
Elvira ManzanoSenior Managing Editor; MIMS
Elvira Manzano
Elvira Manzano Senior Managing Editor; MIMS
Dr Roy HerbstDr Roy Herbst

Adjuvant osimertinib continues to demonstrate an overall survival (OS) benefit over placebo in patients with resected EGFR-mutated (exon 19 del/L858R) non-small cell lung cancer (NSCLC), according to the 8-year exploratory analysis of the phase III ADAURA trial presented at WCLC 2026.

At the May 4, 2026 data cut-off, 8-year OS was 74 percent with osimertinib vs 58 percent with placebo (hazard ratio [HR], 0.53) in the stage II–IIIA population (primary cohort). Median follow-up was 92 and 68.5 months, respectively. [WCLC 2026, abstract PL03.01]

Osimertinib also conferred an OS benefit in the overall stage IB–IIIA population. The 8-year OS was 79 percent with osimertinib vs 64 percent with placebo (HR, 0.52), at a median follow-up of 93.3 and 79.6 months, respectively. Data maturity was 26 percent overall (osimertinib, 20 percent; placebo, 31 percent). Median OS was not reached in either population.

Study investigator Dr Roy Herbst of the Dartmouth Cancer Centre in Lebanon, New Hampshire, US described the findings as “phenomenal.”

“The analysis represents the longest OS follow-up in any adjuvant phase III trial for EGFR-mutated NSCLC,” he told the media at a press conference following his presentation. “The long-term findings further characterize the established survival benefit of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA NSCLC, with or without adjuvant chemotherapy. This is also the first study to establish the new paradigm that bringing the best targeted drugs to patients with earlier-stage disease can delay progression and improve survival.”

Durable benefit

Discussant Dr Antonio Passaro of the European Institute of Oncology in Milan, Italy said the updated data confirm osimertinib’s durable benefit. “We can see that there is no late OS convergence. Osimertinib may do more than delay recurrence. We have a consistent rate of patients in whom we may be curing the disease.”

ADAURA was a global, double-blind, randomized trial involving 682 patients with completely resected, EGFR-mutated stage IB–IIIA NSCLC. Initiated in 2015, the trial randomly assigned patients to receive osimertinib 80 mg once daily (n=339) or placebo (n=343) for up to 3 years. Adjuvant chemotherapy was permitted at the treating physician’s discretion.

The primary endpoint was investigator-assessed disease-free survival (DFS) in patients with stage II–IIIA NSCLC. The key secondary endpoint was OS in the stage II–IIIA and overall populations.

At 2 years, adjuvant osimertinib reduced the risk of disease recurrence or death by 83 percent (HR,0.17; p<0.001) in the stage II–IIIA population and by 80 percent (HR, 0.20; p<0.001) in the overall population. [N Engl J Med 2020;383:1711-1723]

Regulatory significance

Based on these findings, the US FDA approved osimertinib in December 2020 for the adjuvant treatment of resected EGFR-mutated stage IB-IIIA NSCLC. Subsequent guidelines recommended 3 years of adjuvant osimertinib as standard care for this population.

An analysis of the final DFS data showed DFS rates of 70 percent with osimertinib vs 29 percent with placebo [HR, 0.23] in the stage II-IIIA population, and 73 percent vs 38 percent [HR, 0.27] in the overall population, demonstrating osimertinib’s prolonged DFS benefit over placebo. [J Clin Oncol 2023;41:1830–1840]

Results of the planned final OS analysis at the January 27, 2023 data cut-off showed OS rates of 85 percent and 73 percent with osimertinib and placebo, respectively, in the stage II–IIIA population (HR, 0.49; p<0.001). In the stage IB-IIIA population, the corresponding rates were 88 percent and 78 percent (HR, 0.49; p<0.001). [N Engl J Med 2023;389:137-147]

8-year landmark analysis

At WCLC 2026 in Seoul, Korea, Herbst said they had selected the 8-year time point because it corresponds to 5 years after osimertinib treatment had ended. “An OS benefit was consistently observed at 8 years across all predefined subgroups, including patients with or without a smoking history, those younger than 65 years or older, patients at every disease stage, and those with either an exon 19 del or an L858R mutation in EGFR.”

He added that the 8-year data continue to support adjuvant osimertinib as the global standard of care and backbone therapy following complete tumour resection. “If this works, let’s make sure everyone gets EGFR tested,” said Herbst.

The analysis included 431 patients, representing 77 percent of those alive at the time of the final OS analysis in 2023. The remaining 27 percent were censored for lack of further survival data after the final OS analysis.

In addition to the ADAURA findings, a separate US study presented at WCLC 2026 found that many patients could not complete the recommended three-year course of adjuvant osimertinib. At 1 year, only 75 percent remained on treatment; 62 percent at 2 years; and 33 percent at 3 years. Stopping treatment early essentially doubled the risk of recurrence or death. [WCLC 2026, abstract P1.142]

The investigators said that proactively managing adverse events and clearly explaining the benefits and risks of continuing therapy could help patients stay on treatment and improve their outcomes.